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Background
Initial studies suggest immunosuppression may be asso-
ciated with the increased rates of precancerous cervical
lesions observed in HIV-infected compared with HIV-
uninfected individuals, but few studies have large
enough populations to study the effect on invasive can-
cer. To characterize the incidence of cervical cancer
among HIV-infected women in the HAART era, we
examined data from the NA-ACCORD HIV cohort
collaboration of IeDEA.
Materials and methods
This analysis includes data from 13 North American
cohorts of HIV-infected women that collected clinically
confirmed or cancer registry-linked data on invasive cer-
vical cancer. Cervical cancer-free women were followed
from the first HAART era CD4+ measurement (1996
onwards) until the earliest of: cervical cancer diagnosis,
lost to followup, death, or December 2007. Incidence
rate overall, by calendar period, and by first CD4+ cell
count after 1995 (baseline) were standardized for age
using the 2000 U.S. standard population.
Results
Among the 16,467 HIV-infected women free of disease
at baseline, 102 cases of invasive cervical cancer were
reported, yielding an age-standardized incidence rate of
114 per 100,000 person-years (95% CI: 88–139). Of
those cases, 40 (39%) were HAART-naïve at the time of
diagnosis. Among women ≤39, 40-49, and ≥50 years of
age the incidence rates were 122, 142, and 89 per
100,000 person-years, respectively. The age-standardized
incidence rates by calendar periods for 1996-1999, 2000-
2003, and 2004-2007 were 133, 152, and 87 per 100,000
person-years, respectively, showing no trend. The age-
standardized incidence rates by baseline CD4+ cate-
gories of >350, 200-350 and <200 cells/μL were 68, 113,
and 185, respectively, indicating an increasing rate with
declining CD4+ cell count (Ptrend<0.001). Among 13,716
HIV-negative women free of disease in these cohorts,
there were 10 invasive cervical cancers for an incidence
of 12.3 per 100,000 person-years (95% CI 6.6-23), similar
to the age-adjusted SEER population incidence of
8.2 per 100,000 person-years.
Conclusions
In this large collaboration of North American HIV
cohorts, the estimate of cervical cancer incidence was
almost 10-fold higher among HIV-infected than unin-
fected women in these cohorts. Although an effect of
increased sexual risk-taking in HIV-infected women
and/or differences in screening cannot be excluded, the
strong association with lower baseline CD4+ cell count
suggests a single low CD4 measurement may predict
increased cervical cancer risk. It is unclear whether
improvements in HIV-therapies during the HAART era
have influenced cervical cancer rates; although no signif-
icant trend in incidence was observed over time, a
decrease was observed in 2004-07.
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